Explanation of Financial Matters
In the past three years, the company achieved operating revenue of 26985.61 million yuan, 34899.83 million yuan, and 33953.88 million yuan, realizing a profit attributable to the parent company of 1966.90 million yuan, 1305.07 million yuan, and 1648.54 million yuan, respectively. The company's main business profit margin was 44.29%, 40.76%, and 45.22%, respectively. The administrative expenses accounted for 1698.20 million yuan, 1145.91 million yuan, and 751.58 million yuan, accounting for 28.76%, 29.76%, and 40.90% of the total revenue, respectively. During the reporting period, the company's operating income growth rate was 3.32%, 7.17%, 12.46%. The company is actively addressing the challenges in the market and adjusting its business strategies accordingly.
In recent years, the company has responded to changes in the investment environment and the market's demand for its products. The company plans to enhance its investment strategies and improve its operational efficiency. The company's financial situation is expected to improve, with projections indicating a significant increase in revenue and profitability in the coming years.
| Year | Operating Revenue (million yuan) | Profit Attributable to Parent Company (million yuan) | Main Business Profit Margin (%) |
|---|---|---|---|
| 2021 | 26985.61 | 1966.90 | 44.29 |
| 2022 | 34899.83 | 1305.07 | 40.76 |
| 2023 | 33953.88 | 1648.54 | 45.22 |
Market Trends
The overseas market for the Shenzhen market has shown significant growth.
2. Changes in the Pharmaceutical Industry
The company operates in the pharmaceutical manufacturing sector, primarily serving clients in the pharmaceutical industry. Currently, the pharmaceutical industry is undergoing transformation, with innovation and regulatory review accelerating. Domestic and foreign pharmaceutical companies are actively seeking new business opportunities, particularly in the areas of drug development and production. The company has also been focusing on expanding its international business, especially in the pharmaceutical equipment sector, which is expected to reach approximately 78 billion yuan by 2025, according to market research forecasts.
3. Changes in Revenue Structure
During the reporting period, the company's revenue structure is as follows:
| Item | 2025 Year | Amount | Percentage | 2024 Year | Amount | Percentage | 2023 Year | Amount | Percentage |
|---|---|---|---|---|---|---|---|---|---|
| Main Business Income | 30,863.90 | 90.00% | 31,424.54 | 90.04% | 32,632.87 | 87.57% | |||
| Other Business Income | 3,089.98 | 9.00% | 3,475.28 | 9.96% | 3,089.98 | 12.43% | |||
| Total Revenue | 33,953.88 | 100.00% | 34,899.82 | 100.00% | 36,721.85 | 100.00% |
The report indicates that the company's main business income accounts for 90.00% of total revenue, while other business income accounts for 9.00%. The main business income is the core source of the company's revenue, with a focus on sales of pharmaceutical materials and service income.
4. Product Advantages
In comparison to similar products in the industry, the company's main products have clear technological advantages, as outlined below:
| Main Product | Description of Key Technical Indicators |
|---|---|
| Major Product 1 | Features a structure that is suitable for various configurations, adaptable to different operational requirements. |
| Major Product 2 | Designed for high efficiency and reliability, meeting industry standards for performance. |
5. Market Outlook
The company is a leader in the domestic market for biological detection and analysis, with a focus on modern biological testing. The company will continue to strengthen its technological innovation and market competitiveness, aiming to enhance its market share and profitability.